The Office of Translational Research (OTR) at the National Institutes for Neurological Disorders and Stroke (NINDS) has launched a new suite of non-dilutive funding programs to support academic
The Office of Translational Research (OTR) at the National Institutes for Neurological Disorders and Stroke (NINDS) has launched a new suite of non-dilutive funding programs to support academic investigators and small businesses to engage in therapeutic and device discovery and development in neurological disorders. This support begins with assay development through to initial test of clinical candidate in human trials.
OTR has embarked on a sustained campaign to build public-private partnerships to ensure that projects funded by OTR are being appropriately de-risked to support downstream investment from other stakeholders, such as pharma, biotech, venture capital, and patient organizations.
The emerging priorities of the OTR are to ensure that therapeutic development is partnered with the development of mechanistic biomarkers to provide a deeper understanding of the mechanism of action of the therapeutic candidate.
- Rajesh Ranganathan, PhD, Director, Office of Translational Research, NINDS
- Masha Fridkis-Hareli MSc, PhD, Founder and President, ATR, LLC
Our esteemed speaker will describe:
- NINDS’s funding mechanisms
- Results of this campaign to date and
- How funded entities as well as potential funders might be able to benefit.
Come join us for this fascinating presentation and bring your questions.
(Thursday) 8:00 am - 10:00 am
415 Main Street, Cambridge MA